Antithrombotic Drugs (Anticoagulants, Antiplatelets, and Thrombolytics)

Vardanyan, Ruben; Hruby, Victor

doi:10.1016/b978-0-12-411492-0.00024-9

Cited by 3 publications

(1 citation statement)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2001, fondaparinux, a synthetic and selective inhibitor of factor Xa, was registered in the United States and Europe as a new antithrombotic drug. It takes more than 50 steps to synthesize fondaparinux and the overall yield of the process is 0.1% [ 123 ]. Fondaparinux has a molecular weight of 1.728 kDa and is a selective and reversible inhibitor of factor Xa dependent on binding to antithrombin to elicit its activity.…”

Section: Injectablesmentioning

confidence: 99%

The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis

Napolitano,

Siragusa

2023

Cancers

View full text Add to dashboard Cite

Cancer-associated thrombosis (CAT) is a leading cause of death among patients with cancer. CAT can manifest itself as venous thromboembolism (VTE), in the form of deep vein thrombosis or pulmonary embolism, or arterial thromboembolism. The pathophysiology of CAT is complex and depends on cancer-, patient-, treatment- and biomarkers-related factors. Treatment of VTE in patients with cancer is complex and includes three major classes of anticoagulant agents: heparin and its derivatives, e.g., low molecular weight heparins, direct oral anticoagulants (DOACs), and vitamin K inhibitors. Given the tremendous heterogeneity of clinical situations in patients with cancer and the challenges of CAT, there is no single universal treatment option for patients suffering from or at risk of CAT. Initial studies suggested that patients seemed to prefer an anticoagulant that would not interfere with their cancer treatment, suggesting the primacy of cancer over VTE, and favoring efficacy and safety over convenience of route of administration. Recent studies show that when the efficacy and safety aspects are similar, patients prefer the oral route of administration. Despite this, injectables are a valid option for many patients with cancer.

show abstract

Section: Injectablesmentioning

confidence: 99%

The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis

Napolitano,

Siragusa

2023

Cancers

View full text Add to dashboard Cite

show abstract

Synthesis and Evaluation of 5‐(o‐Tolyl)‐1H‐tetrazole Derivatives as Potent Anticonvulsant Agents

Dong¹,

Wang²,

Wang

et al. 2017

Archiv der Pharmazie

View full text Add to dashboard Cite

A series of 5-(o-tolyl)-1H-tetrazole derivatives were synthesized and evaluated for their anticonvulsant activities. 1-(2-Methylbenzyl)-5-(o-tolyl)-1H-tetrazole (3h) showed important anticonvulsant activity against the MES-induced seizures, as well as lower neurotoxicity with an ED value of 12.7 mg/kg and a TD value of over 500 mg/kg after intraperitoneal injection into mice, providing 3h with a high protective index (TD /ED ) of over 39.4. The achieved results prove that the distinctive compounds could be valuable as a model for future development, adaptation, and investigation to construct more active analogues.

show abstract

Direct synthesis of alkylated 4-hydroxycoumarin derivatives via a cascade Cu-catalyzed dehydrogenation/conjugate addition sequence

Chen

et al. 2023

Chem. Commun.

View full text Add to dashboard Cite

show abstract

Antithrombotic Drugs (Anticoagulants, Antiplatelets, and Thrombolytics)

Cited by 3 publications

References 148 publications

The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis

The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis

Synthesis and Evaluation of 5‐(o‐Tolyl)‐1H‐tetrazole Derivatives as Potent Anticonvulsant Agents

Direct synthesis of alkylated 4-hydroxycoumarin derivatives via a cascade Cu-catalyzed dehydrogenation/conjugate addition sequence

Contact Info

Product

Resources

About